UroGen Pharma (URGN) EPS (Basic) (2016 - 2025)
Historic EPS (Basic) for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to -$0.69.
- UroGen Pharma's EPS (Basic) fell 3529.41% to -$0.69 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.46, marking a year-over-year decrease of 1849.32%. This contributed to the annual value of -$2.7 for FY2024, which is 2400.91% up from last year.
- As of Q3 2025, UroGen Pharma's EPS (Basic) stood at -$0.69, which was down 3529.41% from -$1.05 recorded in Q2 2025.
- Over the past 5 years, UroGen Pharma's EPS (Basic) peaked at -$0.51 during Q3 2024, and registered a low of -$1.35 during Q3 2021.
- In the last 5 years, UroGen Pharma's EPS (Basic) had a median value of -$1.05 in 2025 and averaged -$1.01.
- As far as peak fluctuations go, UroGen Pharma's EPS (Basic) skyrocketed by 4240.0% in 2023, and later crashed by 3529.41% in 2025.
- Quarter analysis of 5 years shows UroGen Pharma's EPS (Basic) stood at -$1.27 in 2021, then rose by 1.57% to -$1.25 in 2022, then soared by 42.4% to -$0.72 in 2023, then decreased by 10.78% to -$0.8 in 2024, then grew by 13.49% to -$0.69 in 2025.
- Its EPS (Basic) was -$0.69 in Q3 2025, compared to -$1.05 in Q2 2025 and -$0.92 in Q1 2025.